Eli Lilly's Zepbound doesn't just lead to weight loss, per the company. A 52-week study found a reduction in obstructive sleep apnea in adults with obesity, the company said Wednesday. Obstructive sleep apnea is a condition in which an upper airway blockage during sleep restricts airflow. People with it have a hard time getting adequate sleep and can ultimately suffer heart arrhythmias, heart failure, and death. The company tested the use of Zepbound on adults with obesity and moderate to severe obstructive sleep apnea, with moderate described as at least 15 interruptions to breathing during sleep per hour. One group did use CPAP machines; the other did not, and the number of those sleep events was measured. The results: